Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors-Reference-Cited by-同舟云学术

Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors

Published:2022-04-20 Issue:11 Volume:49 Page:3892-3897
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Montazeri S. Ali,De la Garza-Ramos Cynthia,Lewis Andrew R.,Lewis Jason T.,LeGout Jordan D.,Sella David M.,Paz-Fumagalli Ricardo,Devcic Zlatko,Ritchie Charles A.,Frey Gregory T.,Vidal Lucas,Croome Kristopher P.,McKinney J. Mark,Harnois Denise,Krishnan Sunil,Patel Tushar,Toskich Beau B.

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-022-05776-y.pdf

Reference16 articles.

1. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol. Published online November 2021. https://doi.org/10.1016/j.jhep.2021.11.018

2. Food and Drug Administration USD of H and HS. TheraSphereTM – P200029. Published 2020. Accessed April 25, 2021. https://www.fda.gov/medical-devices/recently-approved-devices/theraspheretm-p200029

3. Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17–29. https://doi.org/10.1016/S2468-1253(20)30290-9.

4. Gabr A, Kulik L, Mouli S, et al. Liver transplantation following yttrium-90 radioembolization: 15-year experience in 207-patient cohort. Hepatology. Published online May 2020. https://doi.org/10.1002/hep.31318

5. DiNorcia J, Florman SS, Haydel B, et al. Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: analysis from the US Multicenter HCC Transplant Consortium. Ann Surg. 2020;271(4):616–24. https://doi.org/10.1097/SLA.0000000000003253.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing Radioembolization Through Personalized Dosimetry;Advances in Clinical Radiology;2024-09

2. Multidisciplinary assessment of tumor response after internal and external radiation therapy for hepatocellular carcinoma;Hepatoma Research;2024-07-24

3. Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres;Journal of Vascular and Interventional Radiology;2024-07

4. Voxel-based tumor dose correlates to complete pathologic necrosis after transarterial radioembolization for hepatocellular carcinoma;European Journal of Nuclear Medicine and Molecular Imaging;2024-06-24

5. Predictive Dosimetry and Outcomes of Hepatocellular Carcinoma Treated by Yttrium-90 Resin Microsphere Radioembolization: A Retrospective Analysis Using Technetium-99m Macroaggregated Albumin SPECT/CT and Planning Software;Journal of Vascular and Interventional Radiology;2024-05